ArticleFrontiers in immunology2025
Spike specific IgG3 and nucleocapsid IgG response in serum serve as distinguishing immunological markers between SARS-CoV-2 infection and vaccination.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Both SARS-CoV-2 infection and COVID-19 vaccines elicit immunological responses. However, it is difficult to distinguish responses generated after vaccination versus natural infection. Methods: We investigated SARS-CoV-2 spike receptor-binding domain (RBD) and nucleocapsid-specific IgG and RBD specific IgG subclasses (IgG1, IgG2, IgG3 and IgG4) responses using ELISA in four different groups; (1) COVID-19 patients (n=39) with varying disease severity and (2) COVID-19 vaccinated individuals (n=24, both adenovirus/mRNA based) (3) vaccinated after infection (n=39) and (4) patients experienced breakthrough infection (n=14), in Bangladesh. Results: Both COVID-19 patients and vaccinees developed robust RBD-specific IgG responses. In contrast, nucleocapsid specific IgG responses were found in patients but not in vaccine recipients. A distinct IgG subclass antibody response was observed in COVID-19 patients compared to COVID-19-vaccinated individuals. Specifically, COVID-19 patients exhibited elevated levels of both IgG1 and IgG3, with IgG3 dominating in the early phase of infection (days 1-7) followed by a subsequent increase in IgG1. Conversely, COVID-19 vaccination predominantly induced IgG1 responses without a concurrent rise in IgG3. This effect was more evident when a significant rise of IgG1 but not IgG3 was observed in patients who received COVID-19 vaccines after 90 days of infection. However, following breakthrough infection, we observed an increase in both IgG1 and IgG3. All of these findings collectively indicate that COVID-19 vaccination predominantly induces IgG1, whereas natural infection can elicit responses in both IgG1 and IgG3 subclasses. Conclusion: The findings highlight RBD-specific IgG3 as well as nucleocapsid IgG as crucial markers for differentiating between vaccination and natural infection and suggest these assays have utility for longitudinal monitoring of vaccinations and for establishing SARS-CoV-2 correlates of protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.